Biocon Limited (NSE:BIOCON)
India · Delayed Price · Currency is INR 357.80
-3.70 (-1.02%)
Apr 22, 2026, 3:30 PM IST
Biocon Revenue
Biocon had revenue of 41.73B INR in the quarter ending December 31, 2025, with 9.20% growth. This brings the company's revenue in the last twelve months to 168.27B, up 13.99% year-over-year. In the fiscal year ending March 31, 2025, Biocon had annual revenue of 152.62B with 3.43% growth.
Revenue (ttm)
168.27B
Revenue Growth
+13.99%
P/S Ratio
3.48
Revenue / Employee
10.25M
Employees
16,420
Market Cap
585.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 152.62B | 5.06B | 3.43% |
| Mar 31, 2024 | 147.56B | 35.82B | 32.05% |
| Mar 31, 2023 | 111.74B | 29.90B | 36.54% |
| Mar 31, 2022 | 81.84B | 10.41B | 14.57% |
| Mar 31, 2021 | 71.43B | 8.43B | 13.37% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Dishman Carbogen Amcis | 27.97B |
| Anthem Biosciences | 20.02B |
| OneSource Specialty Pharma | 14.19B |
| Concord Biotech | 11.59B |
| Blue Jet Healthcare | 10.53B |
| Supriya Lifescience | 7.35B |
| Panacea Biotec | 6.06B |
| Zota Health Care | 4.73B |
Biocon News
- 1 day ago - Biocon secures Health Canada approval for Bosaya and Vevzuo biosimilars - Business Upturn
- 1 day ago - Biocon issues reminder for KYC updates to shareholders with physical holdings - Business Upturn
- 9 days ago - Pharma sector stocks fall today, April 13: Biocon falls 2.35%, Cipla down 1.66%, Ajanta Pharma gains 0.77% - Business Upturn
- 14 days ago - Biocon shares jump over 3% after US FDA nod for diabetes drug Dapagliflozin tablets - Business Upturn
- 14 days ago - Biocon receives U.S. FDA approval for Dapagliflozin tablets - Business Upturn
- 15 days ago - Biocon launches Bosaya and Aukelso biosimilars in the U.S. - Business Upturn
- 20 days ago - Pharma sector stocks fall sharply today: Sun Pharma down 4.89%, Aurobindo Pharma falls 4.48%, Biocon drops 4.67% - Business Upturn
- 23 days ago - Biocon changes name of step-down subsidiary to Biocon Biologics Ireland - Business Upturn